REGN 1908 1909

Drug Profile

REGN 1908 1909

Alternative Names: REGN-1908-1909

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Developer Regeneron Pharmaceuticals
  • Class Allergy immunotherapies; Antiallergics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hypersensitivity

Most Recent Events

  • 06 Sep 2017 REGN 1908 1909 is still in phase I/II development for Hypersensitivity in Netherlands, New Zealand, Sweden and United Kingdom (Regeneron Pharmaceuticals 10-K, February 2017)
  • 01 Dec 2015 Regeneron completes a phase I/II trial in Hypersensitivity in the Netherlands, New Zealand, Sweden and United Kingdom (NCT02127801)
  • 01 Oct 2014 Phase-I/II clinical trials in Hypersensitivity in Netherlands, New Zealand, Sweden, United Kingdom (SC) (NCT02127801)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top